



# Regulatory science for high-risk medical devices: CORE-MD and beyond

## Final Conference

De Warande Club, Brussels (and online)

15<sup>th</sup> March 2024

### Conference objectives:

- ◇ To review the current state of implementation of the EU Medical Device Directives
- ◇ To present the results of the EU Horizon H2020 CORE-MD project (2021–2024)
- ◇ To consider how clinical experts should contribute to the EU regulatory system
- ◇ To consider what developments and reforms are needed.

<b>09:00 – 10:00</b>	<b>Registration</b>
<b>10:10 – 11:00</b>	<b>Welcome</b>
<b>Introduction to the CORE-MD Coordination &amp; Support Action</b>	<b>Alan Fraser</b> , CORE-MD Scientific Coordinator, <i>European Society of Cardiology</i>
<b>10:10 – 11:00</b>	<b>Session 1: Reflections on the European regulatory system for medical devices</b>
	<b>Per Kjærsgaard-Andersen</b> , Chair EU Affairs Committee, <i>European Federation of National Associations of Orthopaedics and Traumatology (Chair)</i>
	<b>Rainer Becker</b> , Director, <i>European Commission, Directorate-General for Health and Food Safety, Medical Products and Innovation (SANTE.D)</i>
	<b>Contribution from Belgian Presidency of EU / Ministry of Health</b>
	<b>Peter Liese</b> , MEP, IVDR Rapporteur, <i>European Parliament</i>
<b>11:00 – 11:30</b>	<b>Coffee break</b>
<b>11:30 – 13:00</b>	<b>Session 2: Main outcomes of the Horizon 2020 CORE-MD project</b>
	<b>Paul Piscoi</b> , Scientific Policy Officer, <i>European Commission, DG SANTE, Medical Devices (SANTE.D.3) (Co-Chair)</i>
	<b>Anne Lübbecke-Wolff</b> , Associate Professor, Division of Orthopaedics and Trauma Surgery, <i>Geneva University Hospitals (Co-Chair)</i>
<b>Clinical evaluation and transparency of evidence</b>	<b>Robert Byrne</b> , Chair of Cardiovascular Research, <i>Royal College of Surgeons of Ireland</i>
<b>Improving the quality of post-market surveillance</b>	<b>Perla Marang-van de Mheen</b> , Associate Professor, <i>Delft University of Technology</i>
<b>Regulation of AI medical devices</b>	<b>Frank Rademakers</b> , Emeritus Professor, <i>Katholieke Universiteit Leuven</i>
<b>Providing medical devices for children</b>	<b>Berthold Koletzko</b> , President, <i>European Academy of Paediatrics</i>
<b>Panel discussion</b>	



<b>13:00 – 14:00</b>	<b>Lunch</b>
<b>14:00 – 15:15</b>	<b>Session 3: Science-based regulatory policy for medical devices</b>
<p><b>Rob Nelissen</b>, Secretary General, <i>European Federation of National Associations of Orthopaedics and Traumatology (Co-Chair)</i></p> <p><b>Rita Redberg</b>, Professor of clinical medicine, <i>University of California, San Francisco (Co-Chair)</i></p>	
<b>Recommendations from the CORE-MD consortium</b>	<b>Alan Fraser</b> , CORE-MD Scientific Coordinator, <i>European Society of Cardiology</i>
<b>Regulatory science at the European Medicines Agency</b>	<b>Miguel Antunes</b> , Senior Scientific Officer, <i>Expert Panels and Groups, European Medicines Agency</i>
<b>The perspective of patients</b>	<b>Penilla Gunther</b> , President, <i>European Patient Safety Foundation</i>
<b>Public responsibilities of the notified bodies</b>	<b>Sabina Hoekstra</b> , Vice President, <i>European Association Notified Bodies for MDs and IVDs</i>
<b>Panel discussion</b>	
<b>15:15 – 15:30</b>	<b>Coffee break</b>
<b>15:30 – 16:30</b>	<b>Session 4: Global regulatory convergence – priorities for development</b>
<p><b>Niall McAleenan</b>, Director of Medical Devices, <i>Health Products Regulatory Authority Ireland (Co-Chair)</i></p> <p><b>Elizabeth Macintyre</b>, President, <i>Biomedical Alliance in Europe (Co-Chair)</i></p>	
<b>Review by the European Commission</b>	Flora Giorgio, Head of Unit, <i>European Commission, DG SANTE, Medical Devices (SANTE.D.3)</i>
<b>The role of the World Health Organization</b>	<b>Adriana Velazquez Berumen</b> , Group Lead Medical Devices and In-Vitro Diagnostics, <i>World Health Organization</i>
<b>The view of European manufacturers</b>	<b>Petra Zoellner</b> , Director Regulatory Affairs (IVDR & MDR), <i>MedTech Europe</i>
<b>Comments from the FDA and IMDRF</b>	<b>Kenneth Cavanaugh</b> , Deputy Director, <i>Office of Health Technology, Cardiovascular Devices, U.S. Food and Drug Administration</i>
<b>Panel discussion</b>	
<b>Summary and conclusion</b>	

All times are CET.

Participation in person is available at no cost on a first-come first-served basis. Live webcasting will be also available. **Pre-registration is required for both in person and online participants at this [link](#).**

